The Global Pemetrexed Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 2,062.5 Mn in 2017, and is projected to exhibit a CAGR of 1.3% during the forecast period (2018–2026), as highlighted in a new report published by Coherent Market Insights.
Approval and launch of affordable generic of Pemetrexed in the market, which is expected to increase its adoption and drive global pemetrexed market growth. Alimta is a patented drug of Eli Lilly and Company, it has vitamin regimen patent in the U.S. and Europe up to 2021 and pediatric exclusivity in the U.S. up to 2022.
However, patent for compound of Alimta expired in the U.S. in January 2017, and expired in major European countries and Japan in December 2015. Hence, key players in the market have developed and gained approval for generic versions of Alimta in key regions.
For instance, in 2017, Eagle Pharmaceuticals Inc. received the U.S. Food and Drug Administration (FDA) approval for its diluted version of Eli Lilly and Co’s blockbuster cancer drug Alimta.
Launch of generic versions of Pemetrexed is expected to increase the affordability of drugs as generic drugs are cost effective. However, it is projected to affect the revenues to Eli Lilly and Company’s branded drug over the forecast period.
Eli Lilly and Company is dedicated to expand the indication of Alimta (Pemetrexed), such expansion of indication is expected to support global Pemetrexed market growth.
For instance, in 2012, Alimta received the FDA approval, as maintenance therapy for locally advanced or metastatic NSCLC, following initial ALIMTA-plus-cisplatin treatment for locally advanced or metastatic nonsquamous NSCLC. In 2018, ALIMTA received FDA approval for an additional indication for the combination with carboplatin plus pembrolizumab as first-line treatment for metastatic nonsquamous NSCLC, irrespective of PD-L1 expression status
Browse 18 Market Data Tables and 20 Figures spread through 130 Pages and in-depth TOC on Global Pemetrexed Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2026
To know the latest trends and insights prevalent in the Pemetrexed market, click the link below:
Alimta is a patented drug of Eli Lilly and Company, hence Eli Lilly and Company is delicately working to prevent the launch of generic version of Alimta in key region such as U.S. from where Alimta generates about 50% of its revenue.
For instance, in June 2018, Eli Lilly and Company got a favorable result from U.S. District Court and prevented Hospira Inc. and India’s Dr. Reddy’s Laboratories from launching generic version of Alimta until the patent expires in 2022.
Key Takeaways of the Pemetrexed Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.